首页> 美国卫生研究院文献>Schizophrenia Bulletin >O12.4. EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST EXENATIDE ON BONE STATUS IN OBESE NON-DIABETIC ANTIPSYCHOTIC-TREATED SCHIZOPHRENIA SPECTRUM PATIENTS

【2h】

O12.4. EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST EXENATIDE ON BONE STATUS IN OBESE NON-DIABETIC ANTIPSYCHOTIC-TREATED SCHIZOPHRENIA SPECTRUM PATIENTS

机译：O12.4。葡糖样肽-1受体激动剂外来肽对肥胖非糖尿病抗精神分裂症患者的骨状态的影响

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Low bone mineral density (BMD) may constitute an underestimated comorbidity in schizophrenia patients undergoing long-term antipsychotic treatment. Glucagon-like peptide 1 (GLP-1) receptor agonists are antidiabetic drugs, which may also affect bone turnover.

机译：在长期接受抗精神病药物治疗的精神分裂症患者中，低骨密度（BMD）可能会低估合并症。胰高血糖素样肽1（GLP-1）受体激动剂是抗糖尿病药，也可能影响骨骼更新。

著录项

期刊名称 Schizophrenia Bulletin
作者
Robert Eriksson; Brian V Broberg; Pelle Lau Ishoy; Nikolaj Bak; Ulrik B Andersen; Niklas R Jørgensen; Filip K Knop; Bjorn Ebdrup;
展开▼
作者单位

展开▼
年(卷),期 2019(45),Suppl 2
年度 2019
页码 -1
总页数 2
原文格式 PDF
正文语种
中图分类精神病学;
关键词

相似文献

外文文献
中文文献
专利

1. Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide to Characterize Its Antiobesity Effects in Diet-Induced Obese Mice [J] . Iwasaki Shinji, Hamada Teruki, Chisaki Ikumi, The Journal of Pharmacology and Experimental Therapeutics: Official Publication of the American Society for Pharmacology and Experimental Therapeutics . 2017,第3期

机译：基于机理的药代动力学/药效学型胰高血糖素肽-1受体激动剂exenatide，以表征饮食诱导的肥胖小鼠的抗病性效应
2. Sustained weight loss after treatment with a glucagon-like Peptide-1 receptor agonist in an obese patient with schizophrenia and type 2 diabetes. [J] . Pelle L Ish?y, Filip K Knop, Tina Vilsb?ll, American journal of psychiatry . 2013,第6期

机译：在患有精神分裂症和2型糖尿病的肥胖患者中，使用胰高血糖素样肽1受体激动剂治疗后，体重持续减轻。
3. Sustained weight loss after treatment with a glucagon-like Peptide-1 receptor agonist in an obese patient with schizophrenia and type 2 diabetes. [J] . Pelle L Ish?y, Filip K Knop, Tina Vilsb?ll, American journal of psychiatry . 2013,第6期

机译：用精神分裂症和2型糖尿病治疗血糖素样肽-1受体激动剂后持续减肥。
4. The effects of obesity and smoking status on the health status of congestive heart failure patients. [D] . Conard, Mark Wayne. 2005

机译：肥胖和吸烟状况对充血性心力衰竭患者健康状况的影响。
5. Bone Status in Obese Non-diabetic Antipsychotic-Treated Patients and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density [O] . Robert Eriksson, Brian V. Broberg, Pelle L. Ishøy, 2018

机译：肥胖非糖尿病经抗精神病药物治疗的患者的骨状态以及胰高血糖素样肽-1受体激动剂艾塞那肽对骨转换标志和骨矿物质密度的影响
6. Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide to Characterize Its Antiobesity Effects in Diet-Induced Obese Mice [O] . Shinji Iwasaki, Teruki Hamada, Ikumi Chisaki, 2017

机译：基于机理的药代动力学/药效学型胰高血糖素肽-1受体激动剂exenatide，以表征饮食诱导的肥胖小鼠的抗病性效应

O12.4. EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST EXENATIDE ON BONE STATUS IN OBESE NON-DIABETIC ANTIPSYCHOTIC-TREATED SCHIZOPHRENIA SPECTRUM PATIENTS

摘要

著录项

相似文献

相关主题

期刊订阅